A5036411818- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- Frailty in Older Adults
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Nutrition and Health in Aging
- Cardiac Structural Anomalies and Repair
- Renal cell carcinoma treatment
- Tissue Engineering and Regenerative Medicine
- Electrospun Nanofibers in Biomedical Applications
- Gastrointestinal Tumor Research and Treatment
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
University of Padua
2017-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2023
Istituto Oncologico Veneto
2020-2023
Hôpital Européen Georges-Pompidou
2023
Ospedale Martini
2023
Université Paris Cité
2023
PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic [mCRC]) relapse postresection. The efficacy postoperative systemic treatment is limited in this setting. Thus, these would greatly benefit from the use a reliable prognostic biomarker, such as circulating tumor DNA (ctDNA) to identify minimal or molecular residual disease (MRD). PATIENTS AND METHODS We analyzed cohort 112 mCRC who had undergone metastatic resection curative intent part PREDATOR clinical trial....
To verify whether both doublet chemotherapy with a modified schedule of fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) monochemotherapy fluorouracil plus leucovorin (5-FU + LV) achieve satisfactory efficacy when regimens are combined panitumumab (PAN) as initial treatment elderly patients RAS/BRAF wild-type metastatic colorectal cancer (mCRC).PANDA (ClinicalTrials.gov identifier: NCT02904031) was an open-label, randomized phase II noncomparative trial in previously untreated age 70...
3511 Background: Preop CTRT is considered the standard of care in management LARC. RT can induce antigen release from a low neoantigen-burden tumor (such as mismatch repair proficient colorectal cancer) and activate dendritic cells leading to CD8+ T lymphocyte-mediated anticancer immune response. In LARC patients, neoadjuvant increases PD-L1 expression cells, strongly suggesting combinatory strategy with PD-1/PD-L1 pathway blockade. Based on such considerations, we have designed AVANA study...
Several uncommon genomic alterations beyond RAS and BRAFV600E mutations drive primary resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC). Our PRESSING panel (including PIK3CA exon 20/AKT1/PTEN mutations, ERBB2/MET amplifications, gene fusions, microsatellite instability-high status) represented a paradigm of negative hyperselection with more precise tailoring EGFR blockade. However, modest proportion hyperselected mCRC has intrinsic...
A majority of patients with metastatic colorectal cancer (mCRC) experience recurrence post curative-intent surgery. The addition adjuvant chemotherapy has shown to provide limited survival benefits when applied all patients. Therefore, a biomarker assess molecular residual disease (MRD) accurately and guide treatment selection is highly desirable for high-risk This feasibility study evaluated the prognostic value tissue comprehensive genomic profiling (CGP)-informed, personalized circulating...
Background: First-line decision making is the key to successful care of mCRC patients and RAS/BRAF status crucial select best targeted agent. In hub centers, a relevant proportion referred from small volume centers may not have standard tissue-based (STB) molecular results available at time first visit (T0). Liquid biopsy (LB) help circumvent these hurdles. Methods: A monoinstitutional prospective head-to-head comparison LB versus (vs.) STB testing was performed in real-world setting....
PARP inhibitors are largely recognized as active drugs in BRCA-mutated breast and ovarian malignancies. In pancreatic ductal adenocarcinoma, the inhibitor olaparib has recently been approved maintenance treatment patients with germline BRCA mutations reaching disease control after a platinum-based first line chemotherapy, proving significant benefit on progression free survival. On other hand, little evidence is available regarding single agent standard adenocarcinoma. A 61-year-old female...
218 Background: Immune checkpoint inhibitors (ICI) showed high efficacy in both first and subsequent lines metastatic colorectal cancer with mismatch repair deficiency (dMMR-mCRC); however, they still fail a minority of patients (pts). In non-preplanned analyses from previous studies, RAS mutations ( RASm) have been related to limited activity ICI monotherapy (ICIm) as compared doublets (ICId) dMMR-mCRC. Emerging data suggest different immunological features presence RASm, resulting lower...
Purpose: Despite a substantial amount of literature on tissue-guided regeneration, decellularization process, repopulation time points and stem cell turnover, more in-depth study the argument is required. Currently, there are plenty reports involving large animals, as well clinical studies facing cardiac repair with decellularized homografts, but no exhaustive rodent models described. The purpose this was to develop such model in rats; preliminary results also herein reported. Material...
5 Background: Advanced squamous cell anal cancer (aSCAC) is a rare and aggressive disease, accounting for poor prognosis high morbidity. No targeted therapies are currently available and, after the first line, no standard treatments approved. Immune checkpoint inhibitors (ICI) showed signs of activity in previous phase I/II trials, but predictive prognostic biomarkers lacking. Anti-EGFR have been tested given rarity KRAS mutations aSCAC, with encouraging results. Earlier preclinical evidence...
3581 Background: The phase II randomized AtezoTRIBE study demonstrated that the addition of atezolizumab (atezo) to first-line FOLFOXIRI plus bevacizumab (bev) prolongs PFS mCRC patients, but benefit is limited among patients with proficient mismatch repair (pMMR) tumours. Among these identifying a subgroup able achieve from immune-checkpoint inhibitors crucial challenge translational research. To this end, we investigated potential predictive role an immunomodulatory gene expression...
4051 Background: Advanced squamous cell anal carcinoma (advSCAC) is a rare disease with poor prognosis. No standard therapies beyond first line are currently available, yet promising activity was documented for the anti-EGFR cetuximab (CET) and anti-PD-1 agents in previous retrospective case series phase I-II studies, respectively. In experimental models combination of EGFR PD-L1 blockade synergistic as led to NK cells activation enhancing ADCC. this trial we aimed evaluate safety anti-PD-L1...
Background: It is intuitively thought that early relapse associated with poor survival after recurrence (SAR) in resected colon cancer (CC) patients, but this has never been formally studied.Methods: We pooled data from stage III patients treated oxaliplatin-based adjuvant therapy two phase trials, to analyze time (TTR) and its relationship SAR. TTR SAR were also studied according molecular status (mismatch repair (MMR), RAS BRAFV600E). Early relapsing defined as having a event within 12...
48 Background: First-line decision making is the key to successful management of mCRC patients (pts). RAS/BRAF status essential choose best targeted agent. In hub centers, a not negligible proportion pts referred from elsewhere may have standard tissue-based (STB) molecular results available at time first oncologic visit (T0). LB help circumvent these hurdles. Methods: A monoinstitutional prospective head-to-head comparison versus (vs) STB testing was conducted in real-world setting....
e24015 Background: Colorectal cancer (CRC) is the second most frequent malignancy in patients (pts) aged 70. Elderly are often excluded by clinical trials; however, improvements quality of life and comorbidities management led to expand access anticancer treatments irrespectively age per se. Finding new tools stratify vulnerability elderly pts crucial guide clinicians therapeutic decisions. G8 timed up go test (TUG) have been related prognosis functional decline affected several solid...